Showing results (101-110 of 504) with videos related to
Sort By:
Pageof 51
Oncotarget|October 25, 2016
Bruton tyrosine kinase inhibitor ONO/GS-4059: from bench to bedsideJingjing Wu, Mingzhi Zhang, Delong LiuJournal of Hematology & Oncology|February 16, 2019
Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemiaJuanjuan Zhao, Yongping Song, Delong LiuCancer Letters|November 15, 2016
EAI045: The fourth-generation EGFR inhibitor overcoming T790M and C797S resistanceShuhang Wang, Yongping Song, Delong LiuExperimental Hematology & Oncology|August 4, 2026
Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual MeetingTiantian Zhang, Heng Jiang, Delong LiuScientific Reports|October 28, 2016
Targeting inflammasome/IL-1 pathways for cancer immunotherapyBeichu Guo, Shunjun Fu, Jinyu Zhang, et al.Frontiers in Immunology|March 3, 2020
The Emerging Roles of Endoplasmic Reticulum Stress in Balancing Immunity and Tolerance in Health and Diseases: Mechanisms and OpportunitiesAnqi Li, No-Joon Song, Brian P Riesenberg, et al.Journal of Hematology & Oncology|October 28, 2010
The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1Saad Z Usmani, Robert D Bona, Gabriela Chiosis, et al.Frontiers in Bioscience : a Journal and Virtual Library|February 28, 2002
An integrated view of the roles and mechanisms of heat shock protein gp96-peptide complex in eliciting immune responseZihai Li, Jie Dai, Hong Zheng, et al.Journal of Hematology & Oncology|March 17, 2018
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficaciesLi-Na Zhang, Yongping Song, Delong LiuJournal of Hematology & Oncology|March 4, 2023
CAR T cell therapy for T cell leukemia and lymphoma: latest updates from 2022 ASH Annual MeetingQiusha Huang, Xiao-Hui Zhang, Delong LiuPageof 51